Pharma

Your Article Summary

See Latest Articles

Repligen Licenses Potential Treatment for Spinal Muscular Atrophy Conference Call Scheduled on October
Repligen, 10/23/09

Repligen Corporation announced that it has entered into an exclusive license agreement with Families of Spinal Muscular Atrophy for intellectual property covering compounds which may have utility in treating Spinal Muscular Atrophy. SMA is an inherited neurodegenerative disease in which a defect in the SMN1 gene results in low levels of the protein SMN and leads to progressive damage to motor neurons, loss of muscle function and, in many patients, early death.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

Quality of trials reported as conference abstracts in China: How well are they reported
International Journal of Technology Assessment in Health Care, 11/05/09

User Groups Prove Helpful
HealthDataManagement, 11/03/09

Salix Pharmaceuticals Reviews American Association For The Study Of Liver Diseases Annual Meeting
Salix Pharmaceuticals, 11/03/09

See All of Conferences/Meetings